These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19633474)

  • 61. Network meta-analysis: importance of appropriate trial selection.
    Edwards SJ; Borrill J
    Value Health; 2010 Aug; 13(5):681-2; author reply 683. PubMed ID: 20345543
    [No Abstract]   [Full Text] [Related]  

  • 62. Re: Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small cell lung cancer.
    Stewart DJ
    J Natl Cancer Inst; 2008 Mar; 100(6):445-6; author reply 446. PubMed ID: 18334712
    [No Abstract]   [Full Text] [Related]  

  • 63. [Prolonged survival of gefitinib treatment in patients with advanced and previously treated non-small cell lung cancer].
    Nishikawa M; Kusano N; Yoshimoto N; Ito M; Kakemizu N; Nozaki M; Fujiwara M; Momiyama M; Kido Y
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1437-40. PubMed ID: 17033233
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Erlotinib in the treatment of NSCLC: current and novel prospects from the ASCO 2006].
    Longo F; Giovanni M
    Tumori; 2006; 92(5):suppl 13-22. PubMed ID: 17168450
    [No Abstract]   [Full Text] [Related]  

  • 65. Decision to adopt medical technology under the National Health Insurance System in Taiwan: case study of new molecular targeted drugs among non-small cell lung cancer patients.
    Chen HL; Shen LJ; Wei CP; Lu HM; Hsiao FY
    J Eval Clin Pract; 2015 Oct; 21(5):808-16. PubMed ID: 26096761
    [TBL] [Abstract][Full Text] [Related]  

  • 66. American Society of Clinical Oncology Annual Meeting 2013.
    Yaqub F
    Lancet Respir Med; 2013 Jul; 1(5):360-1. PubMed ID: 24429195
    [No Abstract]   [Full Text] [Related]  

  • 67. Gefitinib or docetaxel in advanced non-small-cell lung cancer.
    Cullen M; Thatcher N
    Lancet; 2008 Nov; 372(9652):1785-6. PubMed ID: 19027472
    [No Abstract]   [Full Text] [Related]  

  • 68. Overview of clinical trials with epidermal growth factor receptor inhibitors in advanced non-small cell lung cancer.
    Thomas M
    Semin Oncol Nurs; 2002 Nov; 18(4 Suppl 4):20-7. PubMed ID: 12534150
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Gefitinib for refractory advanced non-small-cell lung cancer.
    Tsurutani J; Ballas M; Steinberg SM; Egilsson V; Dennis PA
    Lancet; 2006 Jan; 367(9507):300. PubMed ID: 16443034
    [No Abstract]   [Full Text] [Related]  

  • 70. [New substances in the therapy of head and neck cancer].
    Bogeschdorfer F; Gronau S; Riechelmann H
    Laryngorhinootologie; 2006 Jul; 85(7):520-9; quiz 530-1. PubMed ID: 16791768
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A review of erlotinib and its clinical use.
    Tang PA; Tsao MS; Moore MJ
    Expert Opin Pharmacother; 2006 Feb; 7(2):177-93. PubMed ID: 16433583
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Progressive disease rate as a surrogate endpoint of phase II trials for non-small-cell lung cancer.
    Sekine I; Tamura T; Kunitoh H; Kubota K; Shinkai T; Kamiya Y; Saijo N
    Ann Oncol; 1999 Jun; 10(6):731-3. PubMed ID: 10442198
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis.
    Abdel-Rahman O; Ahmed H; ElHalawani H
    Expert Rev Respir Med; 2016 Feb; 10(2):223-34. PubMed ID: 26558417
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results.
    Breathnach OS; Freidlin B; Conley B; Green MR; Johnson DH; Gandara DR; O'Connell M; Shepherd FA; Johnson BE
    J Clin Oncol; 2001 Mar; 19(6):1734-42. PubMed ID: 11251004
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Oligoprogression].
    Guckenberger M
    Strahlenther Onkol; 2015 May; 191(5):453-5. PubMed ID: 26120651
    [No Abstract]   [Full Text] [Related]  

  • 76. Appendix 7: Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours).
    ESMO Guidelines Committee
    Ann Oncol; 2017 Jul; 28(suppl_4):iv158-iv161. PubMed ID: 28881928
    [No Abstract]   [Full Text] [Related]  

  • 77. Response of malignant thymoma to erlotinib.
    Christodoulou C; Murray S; Dahabreh J; Petraki K; Nikolakopoulou A; Mavri A; Skarlos D
    Ann Oncol; 2008 Jul; 19(7):1361-1362. PubMed ID: 18534960
    [No Abstract]   [Full Text] [Related]  

  • 78. Lung cancer: recent advances.
    Lee P
    Ann Acad Med Singap; 2010 Nov; 39(11):819-21. PubMed ID: 21165519
    [No Abstract]   [Full Text] [Related]  

  • 79. Reporting trends of outcome measures in phase II and phase III trials conducted in advanced-stage non-small-cell lung cancer.
    Ghimire S; Kyung E; Kim E
    Lung; 2013 Aug; 191(4):313-9. PubMed ID: 23715997
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Targeted programmed cell death in lung cancer treatment.
    Zimmerman MP; Mehr SR
    Am J Manag Care; 2014 Mar; 20(5 Spec No.):E3. PubMed ID: 25618630
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.